A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level
Status:
Completed
Trial end date:
2020-08-18
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess pharmacokinetics, dynamics, safety and
tolerability of CiVi007 following single and multiple subcutaneous doses in subjects,
including those on statin therapy